Wockhardt Ltd

Net profit of Wockhardt reported to Rs 78.00 crore in the quarter ended September 2025 as against net loss of Rs 22.00 crore during the previous quarter ended September 2024. Sales declined 3.34% to Rs 782.00 crore in the quarter ended September 2025 as against Rs 809.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales782.00809.00 -3 OPM %22.7613.60 - PBDT144.0046.00 213 PBT91.00-9.00 LP NP78.00-22.00 LP Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live

Wockhardt today announced the submission of New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent Zidebactam-Cefepime injection (WCK 5222, ZAYNICH'). The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria including multidrug-resistant (MDR). In US and EU, more than 8 Million cUTI cases are reported every year, reflecting the global burden of Gram negative infections. This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation. Amidst the escalating global crisis of antimicrobial resistance (AMR), Zidebactam-Cefepime represents a first-in-class '-lactam enhancer and '-lactam combination, introducing a novel mechanism of action to combat some of the most difficult-to-treat infections particularly those that remain unresponsive to approved antibiotics, including those that are recently approved. Clinical and non-clinical studies have demonstrated its potent activity against multi-drug resistant (MDR) and extreme drug resistant (XDR) Gram-negative pathogens, including those harbouring NDM carbapenemases and PBP mutations. A Phase II study undertaken has demonstrated its efficacy against diverse carbapenem-resistant infections. The NDA submission follows the successful completion of a pivotal Phase III global clinical trial (ENHANCE 1), conducted across 64 sites in India, USA, Bulgaria, Estonia, Lithuania, Poland, Slovakia, Mexico, and China. The program is supported by a robust clinical development package, including nine Phase I studies conducted in the U.S. and China, a Phase II study conducted in India and a multinational Phase III trial evaluating efficacy in cUTI, including pyelonephritis. Zidebactam-cefepime has been granted qualified infectious disease product (QIDP) and Fast Track Designation by US FDA. Gram-negative infections have become increasingly difficult to treat due to wide spread resistance to multiple classes of antibiotics. Zaynich' has the potential to treat a broad range of infections caused by MDR or XDR pathogens including Enterobacterales and Pseudomonas aeruginosa and A. baumannii. Powered by Capital Market - Live

Mangalore Refinery And Petrochemicals Ltd, Sammaan Capital Ltd, Bharat Forge Ltd, Petronet LNG Ltd are among the other stocks to see a surge in volumes on NSE today, 29 September 2025.Wockhardt Ltd notched up volume of 67.62 lakh shares by 14:14 IST on NSE, a 14.76 fold spurt over two-week average daily volume of 4.58 lakh shares. The stock rose 15.09% to Rs.1,538.20. Volumes stood at 23.24 lakh shares in the last session.Mangalore Refinery And Petrochemicals Ltd saw volume of 126.1 lakh shares by 14:14 IST on NSE, a 8.43 fold spurt over two-week average daily volume of 14.96 lakh shares. The stock increased 5.46% to Rs.134.35. Volumes stood at 18.44 lakh shares in the last session.Sammaan Capital Ltd saw volume of 1170.26 lakh shares by 14:14 IST on NSE, a 6.25 fold spurt over two-week average daily volume of 187.29 lakh shares. The stock increased 11.67% to Rs.153.91. Volumes stood at 204.12 lakh shares in the last session.Bharat Forge Ltd notched up volume of 47.71 lakh shares by 14:14 IST on NSE, a 4.98 fold spurt over two-week average daily volume of 9.58 lakh shares. The stock rose 3.64% to Rs.1,224.10. Volumes stood at 7.05 lakh shares in the last session.Petronet LNG Ltd notched up volume of 80.94 lakh shares by 14:14 IST on NSE, a 4.65 fold spurt over two-week average daily volume of 17.40 lakh shares. The stock rose 4.68% to Rs.279.40. Volumes stood at 18.95 lakh shares in the last session.Powered by Capital Market - Live

Miqnaf, a proprietary antibiotic discovered and developed by Wockhardt, is the third novel drug from the company's in-house discovery programme. It is intended for the treatment of community-acquired bacterial pneumonia (CABP) and is the first new macrolide to be developed in over three decades. The drug has received Qualified Infectious Disease Product (QIDP) designation from the US FDA, following earlier Phase 1 and Phase 2 studies conducted globally. The Phase 3 trial, involving about 500 patients, compared Miqnaf with moxifloxacin. The study reported non-inferior efficacy, with more than 90% of patients showing improvement within 3-4 days of treatment initiation. Wockhardt said Miqnaf is designed as a once-daily, three-day oral regimen. The company noted that the drug aims to address rising antibiotic resistance, with the Indian Council of Medical Research estimating macrolide resistance at nearly 75% in 2023. Wockhardt is a research based global pharmaceutical and biotech company. On a consolidated basis, Wockhardt reported net loss of Rs 90 crore in Q1 June 2025 as against net loss of Rs 14 crore in Q1 June 2024. Net sales declined 0.14% YoY to Rs 738 crore in Q1 June 2025. Powered by Capital Market - Live

Wockhardt announced that ICRA has upgraded the credit ratings to BBB/ A3+ and revised the outlook from stable to positive for various debt facilities availed by the company. Powered by Capital Market - Live

Wockhardt has allotted 6,600 equity shares under ESOS on 21 August 2025. In view of the above, the paid-up equity share capital of the Company will increase from Rs. 81,24,27,845/- consisting of 16,24,85,569 equity shares of Rs.5/- each to Rs.81,24,60,845/- consisting of 16,24,92,169 equity shares of Rs.5/- each.Powered by Capital Market - Live

Net Loss of Wockhardt reported to Rs 90.00 crore in the quarter ended June 2025 as against net loss of Rs 14.00 crore during the previous quarter ended June 2024. Sales declined 0.14% to Rs 738.00 crore in the quarter ended June 2025 as against Rs 739.00 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales738.00739.00 0 OPM %9.7612.31 - PBDT44.0048.00 -8 PBT-12.00-6.00 -100 NP-90.00-14.00 -543 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live

A clinically challenging case involving Wockhardt's novel antibiotic Zaynich' was recently published in the July 17, 2025 issue of the Journal of Antimicrobial Chemotherapy - AMR, a leading publication by the British Society for Antimicrobial Chemotherapy. The publication details the successful use of Zaynich', a combination of Zidebactam and Cefepime, in treating a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infection'an infection resistant to all available antibiotics in the United States. This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Notably, this patient was infected with two different pathogens - Pseudomonas and Klebsiella, both resistant to all the recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam. The case report detailed the results of genetic analysis of bacterial DNA and determined that Pseudomonas and Klebsiella harbored 4 distinct resistance mechanisms each leading to pan-drug resistance. Initially, the patient was treated for 10 weeks with cefiderocol and eravacycline (a novel tetracycline antibiotic), but the infection persisted, and the Pseudomonas strain became resistant to cefiderocol. The patient continued to suffer from fever and chills, and imaging tests showed new abscesses in the liver ' clear signs that the infection was not under control. Given the high risk of transplant failure due to these MDR infections, a multidisciplinary team, including microbiologists, infectious disease experts, oncologists, and transplant surgeons, sought emergency access to Zaynich'. The antibiotic was administered for 14 days around the time of the liver transplant. The results were remarkable - within 11 days, the patient improved clinically and transferred from ICU to regular floor, and follow-up imaging showed no signs of active infection. Importantly, the patient remained infection-free even after six weeks of completing treatment with Zaynich', making liver transplant successful and allowing doctors to safely resume chemotherapy for the underlying cancer. The authors highlighted the role of Zaynich' as a potential treatment option for extensively drug resistant infections with extremely limited/no treatment options. Zaynich' is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial, which will support its marketing authorization across international markets. Prior to this, multiple Phase I clinical pharmacology studies involving the Zidebactam/Cefepime combination were successfully conducted in the United States. Zaynich' has also completed a multi-indication clinical study in India, specifically targeting carbapenem-resistant infections. To date, more than 50 patients in India and the U.S. suffering from highly resistant infections have been treated with Zaynich' under compassionate use programs. Powered by Capital Market - Live